Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. NKE
8. MU
9. ACN
10. USO

Go back to Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon

Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer

September 20, 2016 1:18 PM EDT

Oppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).

Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate... More

Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush

September 20, 2016 7:21 AM EDT

Wedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $66.00 (from $36.00) after the FDA approved eteplirsen.

Behanna commented, "In line with our expectations after FDA asked for new data, eteplirsen has received accelerated... More

RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target

September 19, 2016 1:52 PM EDT

RBC Capital upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Sector Perform to Outperform with a price target of $83.00 (from $5.00).

Analyst Simos Simeonidis commented, "In one of the most perplexing regulatory decisions in recent history, FDA has granted accelerated approval to Sarepta's eteplirsen.... More